Lina Sui

Lina Sui

Auto-generated profile, based on publicly available information

Lina Sui

Naomi Berrie Diabetes Center and Department of Pediatrics, College of Physicians and Surgeons, Columbia University Medical Center, New York, NY

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 March 2016 in Nature
Verified
Journal Article
Closed access
ISIdo Sagi
Ido Sagi
GCGloryn Chia
Gloryn Chia
TGTamar Golan-Lev
Tamar Golan-Lev
MPMordecai Peretz
Mordecai Peretz
UWUri Weissbein
Uri Weissbein
NBNissim Benvenisty
Nissim Benvenisty

20 September 2017 in Diabetes
Verified
Journal Article
Open access
PDF file
LSLina Sui
Lina Sui
NDNichole Danzl
Nichole Danzl
SCSean R. Campbell
Sean R. Campbell
RVRyan Viola
Ryan Viola
DWDamian Williams
Damian Williams
DEDieter Egli
Dieter Egli
β-Cells derived from stem cells hold great promise for cell replacement therapy for diabetes. Here we examine the ability of nuclear transfer embryonic stem cells (NT-ESs) derived from a patient with type 1 diabetes to differentiate into β-cells and provide a source of autologous islets for cell replacement. NT-ESs differentiate in vitro with an average efficiency of 55% into C-peptide–positive cells, expressing markers of mature β-cells, including MAFA and NKX6.1. Upon transplantation in immunodeficient mice, grafted cells form vascularized islet-like structures containing MAFA/C-peptide–positive cells. These β-cells adapt insulin secretion to ambient metabolite status and show normal insulin processing. Importantly, NT-ES-β-cells maintain normal blood glucose levels after ablation of the mouse endogenous β-cells. Cystic structures, but no teratomas, were observed in NT-ES-β-cell grafts. Isogenic induced pluripotent stem cell lines showed greater variability in β-cell differentiation. Even though different methods of somatic cell reprogramming result in stem cell lines that are molecularly indistinguishable, full differentiation competence is more common in ES cell lines than in induced pluripotent stem cell lines. These results demonstrate the suitability of NT-ES-β-cells for cell replacement for type 1 diabetes and provide proof of principle for therapeutic cloning combined with cell therapy.

1 September 2010 in Diabetes
Verified
Journal Article
Open access
JMJosué Kunjom Mfopou
Josué Kunjom Mfopou
BCBing Chen
Bing Chen
LSLina Sui
Lina Sui
KSKaren Sermon
Karen Sermon
LBLuc Bouwens
Luc Bouwens
Recent studies with human embryonic stem (hES) cells have established new protocols for substantial generation of pancreatic progenitors from definitive endoderm. These findings add to the efficient derivation of definitive endoderm, which is controlled by Wnt and Nodal pathways, and delineate a step forward in the quest for alternative β-cell sources. It also indicates that critical refining of the available strategies might help define a universal protocol for pancreatic differentiation applicable to several cell lines, therefore offering the possibility for transplantation of immune-matched or patient-specific hES–derived β-cells. We appraise here the fundamental role that bone morphogenetic protein, fibroblast growth factor, and retinoid signaling play during pancreas development, and describe a fundamental emergence of their combination in recent studies that generated pancreatic cells from hES cells. We finally enumerate some prospects that might improve further differentiation of the progenitor cells into functional β-cells needed in diabetes cell therapy.

1 January 2013 in The International Journal of Developmental Biology
Verified
Journal Article
Closed access
LSLina Sui
Lina Sui
LBLuc Bouwens
Luc Bouwens
JMJosué K. Mfopou
Josué K. Mfopou
Embryonic stem cells (ESCs) have the potential to be used as unlimited resources for tissue replacement therapy, thereby compensating for organ donor shortage. To reach this goal, the molecular principles governing early differentiation events in the developing embryo need to be addressed, understood and properly implemented in vitro. Studies carried out in several vertebrate models have established that Nodal/Activin A, BMP, WNT and FGF signaling pathways regulate early embryo development and that these pathways are similarly used during germ layer formation by cultured ESCs. However, differences have also been identified in the way these pathways function or interact in mouse vs. human ESCs, making it sometimes difficult to extrapolate findings from one system to the other. In this review, we discuss and compare the role of the relevant signaling pathways and their crosstalk during undifferentiated growth and during the endoderm differentiation of mouse and human ESCs.

2 March 2015 in The EMBO Journal
Verified
Journal Article
Open access
PDF file
BJBjarki Johannesson
Bjarki Johannesson
LSLina Sui
Lina Sui
DFDonald O Freytes
Donald O Freytes
RCRemi Creusot
Remi Creusot
DEDieter Egli
Dieter Egli
The discovery of insulin more than 90 years ago introduced a life‐saving treatment for patients with type 1 diabetes, and since then, significant progress has been made in clinical care for all forms of diabetes. However, no method of insulin delivery matches the ability of the human pancreas to reliably and automatically maintain glucose levels within a tight range. Transplantation of human islets or of an intact pancreas can in principle cure diabetes, but this approach is generally reserved for cases with simultaneous transplantation of a kidney, where immunosuppression is already a requirement. Recent advances in cell reprogramming and beta cell differentiation now allow the generation of personalized stem cells, providing an unlimited source of beta cells for research and for developing autologous cell therapies. In this review, we will discuss the utility of stem cell‐derived beta cells to investigate the mechanisms of beta cell failure in diabetes, and the challenges to develop beta cell replacement therapies. These challenges include appropriate quality controls of the cells being used, the ability to generate beta cell grafts of stable cellular composition, and in the case of type 1 diabetes, protecting implanted cells from autoimmune destruction without compromising other aspects of the immune system or the functionality of the graft. Such novel treatments will need to match or exceed the relative safety and efficacy of available care for diabetes.

7 March 2013 in Stem Cell Reviews and Reports
Verified
Journal Article
Closed access
PDF file
LSLina Sui
Lina Sui
MGMieke Geens
Mieke Geens
KSKaren Sermon
Karen Sermon
LBLuc Bouwens
Luc Bouwens
JMJosué Kunjom Mfopou
Josué Kunjom Mfopou